Lux kicks off trial for uveitis treatment

Lux Biosciences has begun treating patients in a pivotal clinical trial programme of LX211.

Lux Biosciences has begun treating patients in a pivotal clinical trial programme of LX211, a next-generation calcineurin inhibitor, for the treatment of uveitis.

The trial, LUMINATE (Lux Uveitis Multicentre Investigation of a New Approach to TreatmEnt), consists of three controlled, double masked studies investigating the use of LX211 in different forms of active uveitis and in maintaining control in patients with quiescent disease.

The company expects to enrol more than 500 patients at approximately 45 sites across North America, Europe and India. Efficacy will be measured at six months by assessing the degree of inflammation in the anterior and posterior segments of the eye.

Related Videos
Noninfectious uveitis, uveitic macular oedema: A synopsis of frontline therapies
Approaches for managing treatment of patients with endophthalmitis
ARMOR study: Evaluating antibiotic resistance in the treatment of staph infections
Investigating efficacy of OC-02 to stimulate the trigeminal nerve for the treatment of dry eyes
Studying teprotumumab adherence in patients with thyroid eye disease
Corneal cross-linking and epithelial management: four pearls for success
Related Content
© 2023 MJH Life Sciences

All rights reserved.